Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic HBV i

[Guest guest]

DGDispatch

Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic

HBV in Continuing GLOBE trial: Presented at HEP DART

By Bonnie Darves

KOHALA COAST, HI -- December 29, 2005 -- The investigational polymerase

inhibitor telbivudine continues to show strong antiviral activity in chronic

hepatitis B (HBV) when compared with standard treatment with lamivudine,

with the efficacy gap between the two drugs widening as treatment duration

continues.

Eighteen months into treatment, 84% of patients on telbivudine had

undetectable HBV DNA, compared to 67% of lamivudine patients. At that time

point, alanine aminotransferase normalization had occurred in 76% of

participants taking telbivudine versus 64% of subjects on lamivudine.

In an oral session here on December 15th at the Frontiers in Drug

Development for Viral Hepatitis HEP DART 2005 meeting, lead investigator

Ching-Lung Lai, MD, Professor, Department of Medicine, University of Hong

Kong, presented 76-week data of the international, 2-year, randomized,

blinded, phase 3 GLOBE trial.

" In all patient subgroups, telbivudine was looking better than lamivudine at

week 76, and viral breakthrough was seen in only 3% of telbivudine patients,

compared to 10% in the lamivudine [group], " Dr. Lai said.

The study is comparing oral telbivudine at a daily dose of 600 mg with oral

lamivudine at 100 mg daily. Subjects are adults living being in 112 centres

in Asia, Europe and North America.

To date, adverse events have been similar between the two treatment groups.

Upper respiratory infections and headache have occurred in roughly 12% of

patients in each group, and fatigue and nasopharyngitis have been reported

by nearly 11% of all trial participants.

Dr. Lai noted that slightly more patients on telbivudine than on lamivudine

(9% versus 3%) experienced transient creatinine elevations, but he added

that no adverse events have been severe enough to require dose modification

or treatment discontinuation.

One-year results of the trial, which includes 1367 patients randomised 1:1

to receive telbivudine or lamivudine, were presented at the American

Association for the Study of Liver Diseases meeting in San Francisco in

November 2005.

[Presentation title: A Phase III Comparative Trial of Telbivudine (LdT) vs.

Lamivudine for Chronic Hepatitis B: First-year Results from the Large

International GLOBE Trial. Abstract 95]

http://www.docguide.com/news/content.nsf/news/8525697700573E18852570E60058A5A7?O\

penDocument & id=061C33FC2A7F39888525689900589BFE & c= & count=10

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

DGDispatch

Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic

HBV in Continuing GLOBE trial: Presented at HEP DART

By Bonnie Darves

KOHALA COAST, HI -- December 29, 2005 -- The investigational polymerase

inhibitor telbivudine continues to show strong antiviral activity in chronic

hepatitis B (HBV) when compared with standard treatment with lamivudine,

with the efficacy gap between the two drugs widening as treatment duration

continues.

Eighteen months into treatment, 84% of patients on telbivudine had

undetectable HBV DNA, compared to 67% of lamivudine patients. At that time

point, alanine aminotransferase normalization had occurred in 76% of

participants taking telbivudine versus 64% of subjects on lamivudine.

In an oral session here on December 15th at the Frontiers in Drug

Development for Viral Hepatitis HEP DART 2005 meeting, lead investigator

Ching-Lung Lai, MD, Professor, Department of Medicine, University of Hong

Kong, presented 76-week data of the international, 2-year, randomized,

blinded, phase 3 GLOBE trial.

" In all patient subgroups, telbivudine was looking better than lamivudine at

week 76, and viral breakthrough was seen in only 3% of telbivudine patients,

compared to 10% in the lamivudine [group], " Dr. Lai said.

The study is comparing oral telbivudine at a daily dose of 600 mg with oral

lamivudine at 100 mg daily. Subjects are adults living being in 112 centres

in Asia, Europe and North America.

To date, adverse events have been similar between the two treatment groups.

Upper respiratory infections and headache have occurred in roughly 12% of

patients in each group, and fatigue and nasopharyngitis have been reported

by nearly 11% of all trial participants.

Dr. Lai noted that slightly more patients on telbivudine than on lamivudine

(9% versus 3%) experienced transient creatinine elevations, but he added

that no adverse events have been severe enough to require dose modification

or treatment discontinuation.

One-year results of the trial, which includes 1367 patients randomised 1:1

to receive telbivudine or lamivudine, were presented at the American

Association for the Study of Liver Diseases meeting in San Francisco in

November 2005.

[Presentation title: A Phase III Comparative Trial of Telbivudine (LdT) vs.

Lamivudine for Chronic Hepatitis B: First-year Results from the Large

International GLOBE Trial. Abstract 95]

http://www.docguide.com/news/content.nsf/news/8525697700573E18852570E60058A5A7?O\

penDocument & id=061C33FC2A7F39888525689900589BFE & c= & count=10

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

DGDispatch

Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic

HBV in Continuing GLOBE trial: Presented at HEP DART

By Bonnie Darves

KOHALA COAST, HI -- December 29, 2005 -- The investigational polymerase

inhibitor telbivudine continues to show strong antiviral activity in chronic

hepatitis B (HBV) when compared with standard treatment with lamivudine,

with the efficacy gap between the two drugs widening as treatment duration

continues.

Eighteen months into treatment, 84% of patients on telbivudine had

undetectable HBV DNA, compared to 67% of lamivudine patients. At that time

point, alanine aminotransferase normalization had occurred in 76% of

participants taking telbivudine versus 64% of subjects on lamivudine.

In an oral session here on December 15th at the Frontiers in Drug

Development for Viral Hepatitis HEP DART 2005 meeting, lead investigator

Ching-Lung Lai, MD, Professor, Department of Medicine, University of Hong

Kong, presented 76-week data of the international, 2-year, randomized,

blinded, phase 3 GLOBE trial.

" In all patient subgroups, telbivudine was looking better than lamivudine at

week 76, and viral breakthrough was seen in only 3% of telbivudine patients,

compared to 10% in the lamivudine [group], " Dr. Lai said.

The study is comparing oral telbivudine at a daily dose of 600 mg with oral

lamivudine at 100 mg daily. Subjects are adults living being in 112 centres

in Asia, Europe and North America.

To date, adverse events have been similar between the two treatment groups.

Upper respiratory infections and headache have occurred in roughly 12% of

patients in each group, and fatigue and nasopharyngitis have been reported

by nearly 11% of all trial participants.

Dr. Lai noted that slightly more patients on telbivudine than on lamivudine

(9% versus 3%) experienced transient creatinine elevations, but he added

that no adverse events have been severe enough to require dose modification

or treatment discontinuation.

One-year results of the trial, which includes 1367 patients randomised 1:1

to receive telbivudine or lamivudine, were presented at the American

Association for the Study of Liver Diseases meeting in San Francisco in

November 2005.

[Presentation title: A Phase III Comparative Trial of Telbivudine (LdT) vs.

Lamivudine for Chronic Hepatitis B: First-year Results from the Large

International GLOBE Trial. Abstract 95]

http://www.docguide.com/news/content.nsf/news/8525697700573E18852570E60058A5A7?O\

penDocument & id=061C33FC2A7F39888525689900589BFE & c= & count=10

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/

[Guest guest]

DGDispatch

Telbivudine Continues to Show Superior Efficacy over Lamivudine in Chronic

HBV in Continuing GLOBE trial: Presented at HEP DART

By Bonnie Darves

KOHALA COAST, HI -- December 29, 2005 -- The investigational polymerase

inhibitor telbivudine continues to show strong antiviral activity in chronic

hepatitis B (HBV) when compared with standard treatment with lamivudine,

with the efficacy gap between the two drugs widening as treatment duration

continues.

Eighteen months into treatment, 84% of patients on telbivudine had

undetectable HBV DNA, compared to 67% of lamivudine patients. At that time

point, alanine aminotransferase normalization had occurred in 76% of

participants taking telbivudine versus 64% of subjects on lamivudine.

In an oral session here on December 15th at the Frontiers in Drug

Development for Viral Hepatitis HEP DART 2005 meeting, lead investigator

Ching-Lung Lai, MD, Professor, Department of Medicine, University of Hong

Kong, presented 76-week data of the international, 2-year, randomized,

blinded, phase 3 GLOBE trial.

" In all patient subgroups, telbivudine was looking better than lamivudine at

week 76, and viral breakthrough was seen in only 3% of telbivudine patients,

compared to 10% in the lamivudine [group], " Dr. Lai said.

The study is comparing oral telbivudine at a daily dose of 600 mg with oral

lamivudine at 100 mg daily. Subjects are adults living being in 112 centres

in Asia, Europe and North America.

To date, adverse events have been similar between the two treatment groups.

Upper respiratory infections and headache have occurred in roughly 12% of

patients in each group, and fatigue and nasopharyngitis have been reported

by nearly 11% of all trial participants.

Dr. Lai noted that slightly more patients on telbivudine than on lamivudine

(9% versus 3%) experienced transient creatinine elevations, but he added

that no adverse events have been severe enough to require dose modification

or treatment discontinuation.

One-year results of the trial, which includes 1367 patients randomised 1:1

to receive telbivudine or lamivudine, were presented at the American

Association for the Study of Liver Diseases meeting in San Francisco in

November 2005.

[Presentation title: A Phase III Comparative Trial of Telbivudine (LdT) vs.

Lamivudine for Chronic Hepatitis B: First-year Results from the Large

International GLOBE Trial. Abstract 95]

http://www.docguide.com/news/content.nsf/news/8525697700573E18852570E60058A5A7?O\

penDocument & id=061C33FC2A7F39888525689900589BFE & c= & count=10

_________________________________________________________________

Express yourself instantly with MSN Messenger! Download today - it's FREE!

http://messenger.msn.click-url.com/go/onm00200471ave/direct/01/